YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu…
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names. Continue Reading
[Abstract stock market chart with multicolored candlestick patterns and numeric overlays on a dark background. Concept for trading, investing, cryptocurrency markets and digital economy presentations.] vadishzainer/iStock via Getty Images…
(RTTNews) - Even with strong research and disciplined stock selection, an investor may not get every stock pick right. As legendary investor Peter Lynch once said, "In this business, if you're good, you're right six times out of ten. You'r…
Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement expected to yield approximately $110 mi…
Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining an Outperform rating on the shares. The…
Climb Bio Inc (NASDAQ:CLYM) is one of the must-buy small cap stocks to buy. On April 7, BTIG reaffirmed its Buy rating and $8 price target on Climb Bio Inc (NASDAQ:CLYM).FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small C…
DelveInsight Business Research LLP The idiopathic membranous nephropathy market is poised for steady expansion driven by rising disease prevalence, enhanced diagnostic capabilities, and increased adoption of supportive and emerging targete…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 healt…
Climb Bio Inc. (NASDAQ:CLYM) is one of the best biotech penny stocks to buy according to analysts. On December 18, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio to $11 from $9, while maintaining a B…
(RTTNews) - For Climb Bio Inc. (CLYM), 2026 promises to be a data-rich year, with study results from two of its core programs poised to shape the company's strategy and guide subsequent development phases. The company is focused on deliver…
Climb Bio, Inc. WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb…
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted…
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytop…
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership…
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for budoprutug, anti-CD19 mo…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Climb Bio, Inc. (CLYM) is a stock that can certainly grab the attention of many investors, but do its recent returns compar…
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will…
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Climb Bio, Inc. (CLYM) one of those stocks right now? By taking a look at the stock's year-to-date p…
New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areas CAMBRIDGE, Mass., August 19, 2025--(BUSINESS WIRE)--eGenesis, a biotechnology…
There’s a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength…
Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotech company with a market capitalization of $81 million, announced the appointment of Cindy Driscoll as Senior Vice President, Finance, effective June 17, 2025. According to InvestingPro…
Climb Bio (NASDAQ:CLYM [https://seekingalpha.com/symbol/CLYM]) has announced the appointments [https://seekingalpha.com/pr/20140329-climb-bio-appoints-edgar-d-charles-m-d-msc-as-chief-medical-officer] of Edgar D. Charles as its Chief Medic…
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has grante…
By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focuse…
Visit Exec Edge Research for Full Report By Exec Edge Research Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 202…
Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Suppo…
Download the Complete Report Here By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead asset…
Download the Complete Report Here By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead asset…
WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experie…
WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually…